Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LANORINAL vs ALDOMET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.
Relief of tension-type headache,Relief of muscle contraction headache
Hypertension (first-line in pregnancy-induced hypertension),Off-label: treatment of hypertensive crises
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
1.5–2 hours (terminal elimination half-life); clinical context: Renal impairment prolongs half-life (up to 4–6 hours in severe impairment), necessitating dose adjustment.
Acetaminophen is primarily metabolized by glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3); a minor pathway via CYP2E1 produces the toxic metabolite NAPQI. Butalbital is metabolized primarily by hydroxylation via CYP2C19.
Primarily hepatic metabolism via conjugation and O-methylation; also undergoes decarboxylation and deamination. Active metabolites include alpha-methyldopamine and alpha-methylnorepinephrine.
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Renal: ~70% as unchanged drug and metabolites (sulfate conjugate, O-methylated derivatives); fecal/biliary: ~20%; <5% removed by hemodialysis.
99% bound, primarily to albumin.
~10-20% bound to plasma proteins (primarily albumin).
0.15-0.25 L/kg, indicating limited extravascular distribution.
0.2–0.4 L/kg; clinical meaning: Moderate distribution, indicating limited extravascular penetration.
Oral: 70-85%.
Oral: ~50% (range 25-60%) due to first-pass metabolism; IV: 100%.
GFR 30-50 m L/min: administer 75% of normal dose. GFR 10-29 m L/min: administer 50% of normal dose. GFR <10 m L/min: use not recommended.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: interval every 12-24 hours; GFR <10 m L/min: interval every 24-48 hours or 250 mg every 36-48 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75%.
0.02-0.05 mg/kg intravenously or intramuscularly every 4-6 hours as needed; maximum single dose 2 mg.
10 mg/kg/day orally in 2-4 divided doses, increased gradually; maximum 65 mg/kg/day or 3 g/day.
Initiate at 0.5-1 mg intravenously or intramuscularly; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initial dose 250 mg once or twice daily; increase slowly; monitor for hypotension, sedation, and bradycardia; avoid in patients with pre-existing bradycardia or heart block.
Acetaminophen has been associated with cases of acute liver failure, sometimes resulting in liver transplant and death. Hepatotoxicity is often associated with use of acetaminophen in doses exceeding 4000 mg per day and often involves more than one acetaminophen-containing product.
None
Risk of hepatotoxicity with high doses or chronic use of acetaminophen; hypersensitivity reactions including anaphylaxis; risk of CNS depression and respiratory depression with butalbital; potential for abuse, dependence, and withdrawal; interactions with alcohol and other CNS depressants; use with caution in patients with hepatic or renal impairment.
Hepatic toxicity (fatal hepatic necrosis reported); hemolytic anemia (positive Coombs test common, may indicate hemolysis); sedation/drowsiness (impair mental alertness); orthostatic hypotension; caution in renal impairment (dose adjustment required); may cause positive direct Coombs test, which interferes with crossmatching; possible rebound hypertension upon abrupt discontinuation.
Hypersensitivity to acetaminophen, butalbital, or any component; severe hepatic impairment; porphyria; history of addiction to barbiturates; concomitant use with other barbiturates or potent CNS depressants (relative).
Active hepatic disease (acute hepatitis, cirrhosis); prior methyldopa-induced hepatic dysfunction; concurrent MAO inhibitor therapy; hypersensitivity to methyldopa; pheochromocytoma.
Avoid high-fiber foods that may reduce absorption; separate by 1 hour. Limit foods high in potassium (e.g., bananas, oranges) unless advised. Avoid herbal supplements like St. John's Wort and hawthorn.
Avoid excessive sodium intake, as it can counteract the antihypertensive effect. No specific food interactions reported, but alcohol may potentiate hypotension and sedation. Iron supplements may reduce absorption of methyldopa; separate administration by at least 2 hours.
LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No increased risk of major malformations with therapeutic doses; monitor for fetal bradycardia and digoxin toxicity due to increased maternal clearance. Risk of preterm labor and low birth weight from underlying maternal condition (e.g., heart failure).
First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for management of chronic hypertension in pregnancy is common, but consider potential for reduced placental perfusion if maternal blood pressure is excessively lowered.
Digoxin is excreted into breast milk with a milk-to-plasma (M/P) ratio of 0.8–0.9. The relative infant dose is approximately 1–5% of the maternal weight-adjusted dose, generally considered compatible with breastfeeding. Monitor infant for bradycardia and signs of digoxin toxicity (vomiting, arrhythmias).
Methyldopa is excreted into breast milk in small amounts (M/P ratio approximately 0.2-0.5). At typical maternal doses, infant exposure is likely subtherapeutic and considered compatible with breastfeeding. Monitor infant for potential hypotension or sedation.
Pregnancy increases digoxin clearance by 30–50%, particularly in the third trimester. Doses may need to be increased by 30–50% to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 2 weeks, requiring dose reduction. Monitor serum digoxin levels every 1–2 months and adjust dose accordingly.
Pregnancy may increase volume of distribution and renal clearance, potentially reducing methyldopa plasma concentrations. Dose adjustments may be necessary to maintain blood pressure control; monitor and titrate based on maternal blood pressure response. Typical starting dose: 250 mg orally twice daily; maximum up to 3 g/day in divided doses, but lower doses are often effective.
Monitor digoxin levels closely due to narrow therapeutic index. Adjust dose in renal impairment. Check potassium and magnesium levels to avoid arrhythmias. Use with caution in elderly and patients with hypothyroidism.
ALDOMET (methyldopa) is a centrally acting alpha-2 agonist used primarily for hypertension in pregnancy. Monitor for positive direct Coombs test, which can occur in up to 20% of patients on long-term therapy; this may interfere with cross-matching but rarely causes hemolysis. Hepatic adverse effects, including increased liver enzymes and rarely hepatitis, require monitoring. Sedation and dizziness are common initially; titrate dose slowly. Methyldopa may cause orthostatic hypotension; advise patients to rise slowly. A paradoxical pressor response may occur if given with MAO inhibitors.
Take exactly as prescribed; do not skip or double doses.,Report symptoms of toxicity: nausea, vomiting, blurred vision, irregular heartbeat.,Avoid taking with other heart medications unless directed by your doctor.,Maintain a consistent diet regarding potassium intake; avoid licorice.
Take exactly as prescribed; do not skip doses or stop suddenly as this may cause rebound hypertension.,This medication may cause drowsiness, especially at start of therapy; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying positions to minimize dizziness or fainting.,Report any unexplained fever, fatigue, jaundice (yellowing of skin/eyes), or dark urine to your healthcare provider immediately, as these may indicate liver problems.,Notify your doctor if you experience persistent dry mouth, flu-like symptoms, or swelling in the legs.,Regular blood pressure monitoring is essential; keep a log of readings.,Avoid alcohol, as it can increase drowsiness and lower blood pressure further.,Inform all healthcare providers, including dentists, that you are taking this medication.,Do not take any other medications, including over-the-counter products, without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LANORINAL vs ALDOMET, answered by our medical review team.
LANORINAL is a Antihypertensive that works by LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.. ALDOMET is a Central Alpha Agonist Antihypertensive that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist. Its active metabolite, alpha-methylnorepinephrine, stimulates presynaptic alpha-2 receptors in the central nervous system, reducing sympathetic outflow from the brainstem and decreasing peripheral vascular resistance, leading to lowered blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LANORINAL and ALDOMET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LANORINAL is: 1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.. The standard adult dose of ALDOMET is: 250 mg orally twice daily, increased as needed every 2-3 days; usual maintenance 500 mg to 2 g/day in 2-4 divided doses; maximum 3 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LANORINAL and ALDOMET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LANORINAL is classified as Category C. LANORINAL (digoxin) is FDA pregnancy category C. First trimester: No well-controlled studies; animal studies show fetal toxicity at high doses. Second and third trimesters: No incr. ALDOMET is classified as Category C. First trimester: No increased risk of major congenital malformations reported in human studies based on limited data. Second and third trimesters: No known teratogenicity; use for . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.